De-escalation of IBD Therapy: When, Who, and How?

被引:5
|
作者
Waljee, Akbar K. [1 ,2 ,3 ]
Chaisidhivej, Natapat [4 ]
Saini, Sameer D. [1 ,2 ,3 ]
Higgins, Peter D. R. [3 ]
机构
[1] VA Ctr Clin Management Res, Ann Arbor, MI USA
[2] Univ Michigan, Med Sch, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI USA
[4] Mahidol Univ, Bangkok, Thailand
关键词
D O I
10.1093/crocol/otz008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
When patients with inflammatory bowel disease reach clinical remission with biologic therapy, a question that often comes up is, "when can I stop my biologic medication?" This is a question fraught with challenges for both physicians and patients. For physicians, there are valid concerns that stepping down from a successful therapy will lead to relapse and disease exacerbation, and that stepping down could lead to anti-biologic antibodies. For patients, the question is often driven by concerns about long-term side effects and costs of biologics. This review provides an overview of the rationale for, and risks of, withdrawal of IBD therapy. Selected studies have shown how to identify subsets of patients in whom de-escalation can be performed with low risk of relapse. Practical guidance on when and how to de-escalate IBD therapy is provided.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] De-escalation therapy in Candida infections: when and how?
    Mikulska, M.
    MYCOSES, 2015, 58 : 26 - 26
  • [2] De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
    Galli, Mattia
    Angiolillo, Dominick J.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [3] Parenteral nutrition in oxygen escalation/de-escalation in SARS-CoV. When and how
    Quintero, Oscar Ivan O.
    Garcia-Garcia, Maria Paula
    Esquinas, Antonio M.
    CLINICAL NUTRITION ESPEN, 2022, 49 : 675 - 676
  • [4] De-escalation Therapy and Remission
    Nuesslein, H. G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 (09): : 782 - 782
  • [5] Optimising IBD patient selection for de-escalation of anti-TNF therapy to immunomodulator maintenance
    Swann, Rachael
    Boal, Alan
    Squires, Seth Ian
    Lamb, Carly
    Clark, Laura Louise
    Lamont, Selina
    Naismith, Graham
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (01) : 16 - 21
  • [6] Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives
    Mario Cazzola
    Paola Rogliani
    Maria Gabriella Matera
    Drugs, 2015, 75 : 1575 - 1585
  • [7] Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives
    Cazzola, Mario
    Rogliani, Paola
    Matera, Maria Gabriella
    DRUGS, 2015, 75 (14) : 1575 - 1585
  • [8] THE "DE-ESCALATION CONCEPT" AND ANTIBIOTIC DE-ESCALATION: A MISSED OPPORTUNITY?
    Camargo, Luis Fernando A.
    SHOCK, 2013, 39 (07): : 29 - 31
  • [9] On the escalation and de-escalation of conflict
    Lacomba, Juan A.
    Lagos, Francisco
    Reuben, Ernesto
    van Winden, Frans
    GAMES AND ECONOMIC BEHAVIOR, 2014, 86 : 40 - 57
  • [10] CONFLICT - ESCALATION AND DE-ESCALATION
    BONOMA, TV
    SAGE PROFESSIONAL PAPER IN INTERNATIONAL STUDIES SERIES, 1975, 3 (0203): : 5 - 85